Nov. 29 at 4:26 AM
$SXTP Are you looking for a biotech company with **disruptive technology**, targeting a **huge unmet clinical need**, and poised for a **revaluation**? Focus on **60 Degrees Pharmaceuticals (SXTP.US)**.
**The enormous potential of its core product is being overlooked by the market!**
* The company's flagship product, Arakoda®, is an FDA-approved malaria preventative drug, but its true value lies in expanding its indication for **babesiosis**.
* **Babesiosis** is a potentially deadly tick-borne disease for which there is currently **no specific preventative treatment available globally**. This is a blue ocean market valued at over **
$1.X billion**!
* The company's collaborative research with Yale University and Mount Sinai Hospital is progressing rapidly, and **patient recruitment has begun for the B-FREE clinical trial**. If successful, Arakoda® will become the **first and only preventative therapy in this field**, a first-to-market position that will bring unparalleled competitive
